Disease modifying therapies in heart failure: an update
- 1 March 2025
- journal article
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 118 (9) , 629-630
Abstract
There is currently limited evidence-based disease-modifying pharmacotherapy in patients with heart failure and mildly reduced/preserved ejection fraction (HFmrEF/HFpEF), forming an unmet clinical need in contemporary heart failure care. However, according to the findings from recent clinical trials with some medications such as finerenone and glucagon-like peptide-1 receptor agonist, a clinical concept of pharmacological therapy in patients with HFmrEF/HFpEF will be updated and upgraded. Based on recent evidence, we herein aim to discuss the possible roles of those medications in the HFmrEF/HFpEF therapy and propose an emerging pharmacological strategy for this population.Keywords
Funding Information
- Nakatomi Foundation
This publication has 9 references indexed in Scilit:
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and ObesityNew England Journal of Medicine, 2025
- Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart FailureCirculation, 2025
- Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection FractionNew England Journal of Medicine, 2024
- Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysisThe Lancet, 2024
- Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trialsThe Lancet, 2024
- Patient Phenotype Profiling in Heart Failure with Preserved Ejection Fraction to Guide Therapeutic Decision Making. A Scientific Statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of HypertensionEuropean Journal of Heart Failure, 2023
- Heart Failure With Preserved Ejection FractionJACC, 2023
- 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection FractionJACC, 2023
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Journal of Heart Failure, 2022